JPMorgan Chase & Co. Boosts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $117.00
Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) had its target price increased by JPMorgan Chase & Co. from $104.00 to $117.00 in a research note published on Thursday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biopharmaceutical company’s stock. Several other analysts also recently weighed in on the stock. HC Wainwright reiterated […]
Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) had its target price increased by JPMorgan Chase & Co. from $104.00 to $117.00 in a research note published on Thursday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biopharmaceutical company’s stock. Several other analysts also recently weighed in on the stock. HC Wainwright reiterated […]
